Molecular characterization of ciprofloxacin resistance of gonococcal strains in Spain

Sexually Transmitted Diseases

Volumn 30, Issue 5, 2003, Pages 395-398

  Alcala B ^a   Arreaza, L ^a   Salcedo, C ^a   Antolin I ^b   Borrell, N ^c   Cacho, J ^d   De Las Cuevas, C ^e   Otero, L ^f   Sauca, G ^g   Vazquez F ^h   Villar, H ⁱ   Vazquez J A ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Hospital Princesa Sofia   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^d HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL DE CABUEÑES   (Spain)

^g HOSPITAL DE MATARÓ   (Spain)

^h HOSPITAL MONTE NARANCO   (Spain)

ⁱ HOSPITAL SAN AGUSTÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CORRELATION ANALYSIS; GENE AMPLIFICATION; GENE FREQUENCY; GENE SEQUENCE; GYRA GENE; GYRB GENE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; NEISSERIA GONORRHOEAE; NONHUMAN; PARC GENE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SPAIN; STRAIN DIFFERENCE;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NEISSERIA GONORRHOEAE; PHENOTYPE; SPAIN;

EID: 0037518498     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200305000-00004     Document Type: Article

References (27)

1. Centers for Disease Control and Prevention. Guidelines for treatment of sexually transmitted diseases. MMWR Morbid Mortal Wkly Rep 1998; 47(RR-1).
2. Ison CA, Dillon JAR, Tapsall JW. The epidemiology of global antibiotic resistance among Neisseria gonorrhoeae and Haemophilus ducreyi. Lancet 1998; 351(Suppl III):8-11.
3. Knapp JS, Fox KK, Trees DL, Whittington WL. Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerg Infect Dis 1997; 3:33-39.
4. Ross JD. Fluoroquinolone resistance in gonorrhea: how, where and so what. Int J STD AIDS 1998; 9:318-322.
5. WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme. Resistance in gonococci isolated in the WHO Western Pacific region to various antimicrobials used in the treatment of gonorrhoea, 1997. Commun Dis Intell 1998; 22:288-291.
6. Deguchi T, Yasuda M, Asano M, et al. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1995; 29:561-563.
7. Su X, Lind I. Molecular basis of high-level ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Denmark from 1995 to 1998. Antimicrob Agents Chemother 2001; 45:117-123.
8. Trees DL, Sandul AL, Whittington WL, Knapp JS. Identification of novel mutation patterns in the parC gene of ciprofloxacin-resistant isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1998; 42:2103-2105.
9. Deguchi T, Yasuda M, Nakano M, et al. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother 1996; 40:1020-1023.
10. Berrón S, Vázquez JA, Jiménez MJ, de la Fuente L, Aguilar L. In vitro susceptibilities of 400 Spanish isolates of Neisseria gonorrhoeae to gemifloxacin and 11 antimicrobial agents. Antimicrob Agents Chemother 2000; 44:2543-2544.
11. Otero L, Alcalá B, Varela JA, Miguel MD, Vázquez JA, Vázquez F. First isolate of a Neisseria gonorrhoeae strain associated with an ofloxacin treatment failure in Spain: case report. Sex Transm Dis 2001; 28:576-578.
12. Anonymous. Bol Epidem Sem 2001; 9:297.
13. De la Fuente L, Vázquez JA. Analysis of genetic variability of penicillinase nonproducing Neisseria gonorrhoeae strains with different levels of resistance to penicillin. J Med Microbiol 1992; 37:96-99.
14. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement. NCCLS document M100-S12. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 2002.
15. Tanaka M, Nakayama H, Haraoka M, Saika T, Kobayashi I, Naito S. Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993-1998. J Clin Microbiol 2000; 38:521-525.
16. Deguchi T, Yasuda M, Nakano M, et al. Uncommon occurrence of mutations in the gyrB gene associated with quinolone resistance in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1996; 40:2437-2438.
17. Tanaka M, Nakayama H, Haraoka M, Saika T, Kobayashi I, Naito S. Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics. Antimicrob Agents Chemother 2000; 44:192-195.
18. Belland RJ, Morrison SG, Ison CA, Huang WM. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol 1994; 14:371-380.
19. Trees DL, Sandul AL, Neal SN, Higa H, Knapp JS. Molecular epidemiology of Neisseria gonorrhoeae exhibiting decreased susceptibility and resistance to ciprofloxacin in Hawaii, 1991-1999. Sex Transm Dis 2001; 28:309-314.
20. Shultz TR, Tapsall JW, White PA. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC. Antimicrob Agents Chemother 2001; 45:734-738.
21. Weigel LM, Anderson GJ, Facklam RR, Tenover FC. Genetic analysis of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45:3517-3523.
22. Ison CA, Woodford PJ, Madders H, Claydon E. Drift in the susceptibility of Neisseria gonorrhoeae to ciprofloxacin and emergence of therapeutic failure. Antimicrob Agents Chemother 1998; 42:2919-2922.
23. Hagman KE, Pan W, Spratt BG, Balthazar JT, Judd RC, Shafer WM. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modified by the mtrRCDE efflux system. Microbiology 1995; 141:611-622.
24. Gill MJ, Simjee S, Al-Hattawi K, Robertson BD, Easmon SF, Ison CA. Gonococcal resistance to β-lactams, and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob Agents Chemother 1998; 42:2799-2803.
25. Bygdeman SM. Polyclonal and monoclonal antibodies applied to the epidemiology of gonococcal infection. In: Young H, McMillan A, eds. Immunological Diagnosis of Sexually Transmitted Diseases. 1988:123-126.
26. Poole K. Outer membranes and efflux: the path to multidrug resistance in gram negative bacteria. Curr Pharm Biotechnol 2002; 3:77-98.
27. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 1994; 264:382-388.